[go: up one dir, main page]

EA200701228A1 - Стабильные композиции фенофибрата с эфирами жирных кислот - Google Patents

Стабильные композиции фенофибрата с эфирами жирных кислот

Info

Publication number
EA200701228A1
EA200701228A1 EA200701228A EA200701228A EA200701228A1 EA 200701228 A1 EA200701228 A1 EA 200701228A1 EA 200701228 A EA200701228 A EA 200701228A EA 200701228 A EA200701228 A EA 200701228A EA 200701228 A1 EA200701228 A1 EA 200701228A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fatty acid
phenophibrate
stable compositions
acid ethers
fenofibrate
Prior art date
Application number
EA200701228A
Other languages
English (en)
Inventor
Джордж Боботас
Рулоф М.Л. Ронген
Original Assignee
Релайэнт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Релайэнт Фармасьютикалз, Инк. filed Critical Релайэнт Фармасьютикалз, Инк.
Publication of EA200701228A1 publication Critical patent/EA200701228A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Фармацевтическая композиция в стандартной дозированной форме из фенофибрата и системы растворителей из эфиров жирных кислот, причем фенофибрат, по существу, растворен в системе растворителей.
EA200701228A 2004-12-06 2005-12-05 Стабильные композиции фенофибрата с эфирами жирных кислот EA200701228A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63312604P 2004-12-06 2004-12-06
PCT/US2005/044036 WO2006062933A2 (en) 2004-12-06 2005-12-05 Stable compositions of fenofibrate with fatty acid esters

Publications (1)

Publication Number Publication Date
EA200701228A1 true EA200701228A1 (ru) 2007-12-28

Family

ID=36578470

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701228A EA200701228A1 (ru) 2004-12-06 2005-12-05 Стабильные композиции фенофибрата с эфирами жирных кислот

Country Status (12)

Country Link
US (1) US20060188529A1 (ru)
EP (1) EP1830804A2 (ru)
JP (1) JP2008522972A (ru)
KR (1) KR20070098855A (ru)
CN (1) CN101094647A (ru)
AU (1) AU2005314197A1 (ru)
BR (1) BRPI0518426A2 (ru)
CA (1) CA2589656A1 (ru)
EA (1) EA200701228A1 (ru)
MX (1) MX2007006775A (ru)
NO (1) NO20073457L (ru)
WO (1) WO2006062933A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070052760A (ko) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 페노피브레이트 제제 및 관련된 치료방법
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
MX2011006307A (es) * 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
US8633252B2 (en) * 2009-01-26 2014-01-21 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
WO2000037057A2 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
AU4017500A (en) * 1999-03-31 2000-10-16 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability

Also Published As

Publication number Publication date
AU2005314197A1 (en) 2006-06-15
JP2008522972A (ja) 2008-07-03
WO2006062933A2 (en) 2006-06-15
NO20073457L (no) 2007-09-05
EP1830804A2 (en) 2007-09-12
CN101094647A (zh) 2007-12-26
BRPI0518426A2 (pt) 2008-11-25
WO2006062933A3 (en) 2006-08-31
US20060188529A1 (en) 2006-08-24
CA2589656A1 (en) 2006-06-15
KR20070098855A (ko) 2007-10-05
MX2007006775A (es) 2008-02-25

Similar Documents

Publication Publication Date Title
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
AR047928A1 (es) Derivados de tetrahidropiridoindol
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
EA201290596A1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
NO20073457L (no) Stabile sammensetninger av fenofibrat med fettsyreestere
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
IL191312A0 (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
WO2009063222A3 (en) Solid compositions
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
SV2008003106A (es) Composicion farmaceutica estable que contiene docetaxel y un metodo para fabricarla
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
AR050851A1 (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
BRPI0507897A (pt) formulação de droga sólida
PE20050923A1 (es) Composicion solida que comprende un sensibilizador de insulina, un secretagogo de insulina y un ester de acidos grasos
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
MX2007006908A (es) Estabilizacion de esteres de glucocorticoides con acidos.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
CY1107277T1 (el) Βενζισοξαζολες